$1.46
3.31% yesterday
Nasdaq, Aug 26, 10:00 pm CET
ISIN
US00509G2093
Symbol
ABOS

Acumen Pharmaceuticals Inc Stock price

$1.46
+0.00 0.00% 1M
+0.16 12.31% 6M
-0.26 15.12% YTD
-1.48 50.34% 1Y
-4.03 73.41% 3Y
-18.64 92.74% 5Y
-18.64 92.74% 10Y
-18.64 92.74% 20Y
Nasdaq, Closing price Tue, Aug 26 2025
-0.05 3.31%
ISIN
US00509G2093
Symbol
ABOS
Industry

Key metrics

Basic
Market capitalization
$91.5m
Enterprise Value
$-22.0m
Net debt
positive
Cash
$143.4m
Shares outstanding
60.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.8
Financial Health
Equity Ratio
76.1%
Return on Equity
-56.1%
ROCE
-97.9%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-143.8m | $-147.1m
EBIT
$-144.0m | $-138.0m
Net Income
$-136.7m | $-141.9m
Free Cash Flow
$-118.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-88.2% | -29.2%
EBIT
-88.1% | -21.0%
Net Income
-108.8% | -39.1%
Free Cash Flow
-114.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.3
FCF per Share
$-2.0
Short interest
3.1%
Employees
61
Rev per Employee
$0.0
Show more

Is Acumen Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Acumen Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Acumen Pharmaceuticals Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Acumen Pharmaceuticals Inc forecast:

Buy
91%
Hold
9%

Financial data from Acumen Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
2% 2%
-
- Research and Development Expense 124 124
120% 120%
-
-144 -144
88% 88%
-
- Depreciation and Amortization 0.18 0.18
50% 50%
-
EBIT (Operating Income) EBIT -144 -144
88% 88%
-
Net Profit -137 -137
109% 109%
-

In millions USD.

Don't miss a Thing! We will send you all news about Acumen Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Acumen Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about 8 hours ago
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
Neutral
Seeking Alpha
14 days ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Director Eric Siemers - Chief Medical Officer James Doherty - President & Chief Development Officer Matt Zuga - CFO & Chief Business Officer Conference Call Participants Jason Eron Zemansky - BofA Se...
Neutral
GlobeNewsWire
15 days ago
NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2025 and provided a business update.
More Acumen Pharmaceuticals Inc News

Company Profile

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Livermore, CA.

Head office United States
CEO Daniel O'Connell
Employees 61
Founded 1996
Website acumenpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today